



PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07C 47/546, 43/20, C07D 211/06, 211/20, 207/04, 223/02, 265/30, A61K 31/33, 31/40, 31/135, 31/445, 31/535	A1	(11) International Publication Number: WO 98/08797 (43) International Publication Date: 5 March 1998 (05.03.98)
(21) International Application Number: PCT/US97/14896 (22) International Filing Date: 22 August 1997 (22.08.97) (30) Priority Data: 60/025,125 / 29 August 1996 (29.08.96) / US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BRYANT, Henry, U [US/US]; 7840 Camelback Drive, Indianapolis, IN 46250 (US); CROWELL, Thomas, A. [US/US]; 5871 Broadway Street, Indianapolis, IN 46220 (US); JONES, Charles, D. [US/US]; 223 East Brunswick Avenue, Indianapolis, IN 46227 (US); PALKOWITZ, Alan, D. [US/US]; 10737 Kingsmill Drive, Carmel, IN 46032 (US) (74) Agents: STRODE, Janelle, D. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>	

(54) Title: NAPHTHYL COMPOUNDS, INTERMEDIATES, COMPOSITIONS, AND METHODS OF USE**(57) Abstract**

The invention are naphthyl compounds of formula (I), wherein R¹ is -H, -OH, -O(C₁-C₄ alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C₁-C₆ alkyl), -O(CO)O(C₁-C₆ alkyl), or -OSO₂(C₄-C₆ alkyl); R² is -H, -F, -Cl, -OH, -O(C₁-C₄ alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C₁-C₆ alkyl), -O(CO)O(C₁-C₆ alkyl), or -OSO₂(C₄-C₆ alkyl); R³ and R⁴ are, independently, -H, -F, -Cl, CH₃, -OH, -O(C₁-C₄ alkyl), OCOAr where Ar is phenyl or substituted phenyl, -OCO(C₁-C₆ alkyl), -O(CO)O(C₁-C₆ alkyl), or -OSO₂(C₄-C₆ alkyl), with the proviso that both R³ and R⁴ cannot be hydrogen; n is 2 or 3; and R⁵ is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof, their intermediates, compositions and method of use.



(I)